share_log

Novo Integrated Sciences | 8-K: Current report

Novo Integrated Sciences | 8-K: Current report

Novo Integrated Sciences | 8-K:重大事件
美股SEC公告 ·  06/25 17:01

Moomoo AI 已提取核心信息

Novo Integrated Sciences, Inc. has announced amendments to executive agreements with two key officers. On June 18, 2024, the company extended the term of the agreement with Robert Mattacchione, the CEO and Chairman of the Board, until June 18, 2025. This amendment follows the original executive agreement made on June 18, 2021, with GPE Global Holdings Inc., an entity controlled by Mattacchione. Similarly, an amendment was made to the executive agreement with Christopher David, extending his term as the Chief Operating Officer until June 18, 2025, and updating his title from President and Chief Operating Officer to solely Chief Operating Officer. These amendments are detailed in Exhibits 10.1 and 10.2, respectively, and are part of the company's Form 8-K filing with the SEC. The company's common stock is listed on the Nasdaq Capital Market under the trading symbol NVOS.
Novo Integrated Sciences, Inc. has announced amendments to executive agreements with two key officers. On June 18, 2024, the company extended the term of the agreement with Robert Mattacchione, the CEO and Chairman of the Board, until June 18, 2025. This amendment follows the original executive agreement made on June 18, 2021, with GPE Global Holdings Inc., an entity controlled by Mattacchione. Similarly, an amendment was made to the executive agreement with Christopher David, extending his term as the Chief Operating Officer until June 18, 2025, and updating his title from President and Chief Operating Officer to solely Chief Operating Officer. These amendments are detailed in Exhibits 10.1 and 10.2, respectively, and are part of the company's Form 8-K filing with the SEC. The company's common stock is listed on the Nasdaq Capital Market under the trading symbol NVOS.
Novo Integrated Sciences,Inc.宣布修改两位关键员工的执行协议。2024年6月18日,公司与首席执行官兼董事长Robert Mattacchione的协议期限延长至2025年6月18日。该修正案遵循了与Mattacchione掌控的GPE Global Holdings Inc.于2021年6月18日签署的原始执行协议。同样,Christopher David的执行协议也进行了修改,他的任期延长至2025年6月18日,职务从总裁兼首席运营官变为单一的首席运营官。这些修正案分别详见展示文件10.1和10.2,并已经包含在8-K表格中提交给美国证券交易委员会(SEC)。该公司的普通股在纳斯达克资本市场上挂牌交易,交易标的为NVOS。
Novo Integrated Sciences,Inc.宣布修改两位关键员工的执行协议。2024年6月18日,公司与首席执行官兼董事长Robert Mattacchione的协议期限延长至2025年6月18日。该修正案遵循了与Mattacchione掌控的GPE Global Holdings Inc.于2021年6月18日签署的原始执行协议。同样,Christopher David的执行协议也进行了修改,他的任期延长至2025年6月18日,职务从总裁兼首席运营官变为单一的首席运营官。这些修正案分别详见展示文件10.1和10.2,并已经包含在8-K表格中提交给美国证券交易委员会(SEC)。该公司的普通股在纳斯达克资本市场上挂牌交易,交易标的为NVOS。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息